CFO Anthony Bergmann and General Counsel Karen Krasney exercised 48,200 options at $3.18 and sold shares at $30.38 for $1.46 million on June 25. Capricor’s stock fell 10% to a four-month low as its Duchenne muscular dystrophy therapy Deramiocel heads to an FDA advisory panel on July 29.
On June 25, CFO Anthony Bergmann and General Counsel Karen Krasney each exercised 24,100 stock options at $3.18 and sold all 48,200 shares at an average price of $30.38, generating approximately $1.46 million in gross proceeds under 10b5-1 trading plans.
Following the filings, Capricor’s stock declined by 10% to close at a four-month low, marking its second consecutive down session with shares ending around $23.80.
Capricor’s Duchenne muscular dystrophy therapy Deramiocel is slated for an FDA advisory committee discussion on July 29, supporting its BLA with Phase 2 Hope-2, long-term extension, and positive Phase 3 Hope-3 results showing a sub-5-point decline in upper-limb function over five years versus a 12-point decline with standard care; the PDUFA target date is August 22.
